Fluid biopsy for solid tumors: A patients companion for lifelong characterization of their disease

Future Oncology

Volumn 8, Issue 8, 2012, Pages 989-998

  Nieva, Jorge J ^a   Kuhn, Peter ^b  

^a BILLINGS CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

cancer diagnosis; circulating tumor cell; fluid biopsy; prognostic indicator

Indexed keywords

CYTOKERATIN; EPITHELIAL CELL ADHESION MOLECULE; MESSENGER RNA;

ANALYTICAL EQUIPMENT; BIOCHIP; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CELL INTERACTION; CIRCULATING TUMOR CELL; COLON CANCER; DENSITY GRADIENT; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EX VIVO STUDY; FLOW CYTOMETRY; FLUID BIOPSY; GENE EXPRESSION; HUMAN; IMMUNODETECTION; INVASIVE PROCEDURE; LUNG CANCER; MEDICAL DECISION MAKING; MELANOMA; METASTASIS; MULTIPLE CANCER; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; UPREGULATION;

BIOPSY; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84865213060     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.91     Document Type: Review

References (62)

1. Cancer Facts & Figures 2011. American Cancer Society, GA, USA (2011).
2. Hardy D, Chan W, Liu CC et al. Racial disparities in length of stay in hospice care by tumor stage in a large elderly cohort with non-small cell lung cancer. Palliat. Med. 26(1), 61-71 (2012).
3. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N. Engl. J. Med. 361(10), 1018-1020 (2009).
4. Doroshow JH. Targeting EGFR in non-small-cell lung cancer. N. Engl. J. Med. 353(2), 200-202 (2005).
5. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005).
6. Bonadonna G, Valagussa P, Tancini G, Di Fronzo G. Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother. Pharmacol. 4(1), 37-41 (1980).
7. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
8. Eiermann W. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann. Oncol. 12(Suppl. 1), S57-S62 (2001).
9. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19(10), 2722-2730 (2001).
10. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19(10), 2587-2595 (2001).
11. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004-1012 (2011).
12. Ou SH, Bazhenova L, Camidge DR et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 5(12), 2044-2046 (2010).
13. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
14. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
15. Nagasaka T, Sasamoto H, Notohara K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J. Clin. Oncol. 22(22), 4584-4594 (2004).
16. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
17. Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15(11), 1164-1168 (2010).
18. Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet. Cytogenet. 139(1), 30-33 (2002).
19. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100(8), 3041-3044 (2002).
20. Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood 100(3), 1105 (2002).
21. Kosaka T, Yatabe Y, Endoh H et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12(19), 5764-5769 (2006).
22. Gow CH, Shih JY, Chang YL, Yu CJ. Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. PLoS Med. 2(9), e269 (2005).
23. Daniel VC, Marchionni L, Hierman JS et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69(8), 3364-3373 (2009).
24. Ashworth T. A case of cancer in which cells similar to those in the tumors were seen in blood after death. Aust. Med. J. 14, 146-147 (1869).
25. Braun S, Muller M, Hepp F, Schlimok G, Riethmuller G, Pantel K. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl Cancer Inst. 90(14), 1099-1101 (1998).
26. Pantel K, Izbicki JR, Angstwurm M et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res. 53(5), 1027-1031 (1993).
27. Pantel K, Braun S, Schlimok G, Riethmuller G. Micrometastatic tumour cells in bone marrow in colorectal cancer. Lancet 341(8843), 501 (1993).
28. Fehm T, Braun S, Muller V et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107(5), 885-892 (2006).
29. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342(8), 525-533 (2000).
30. Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 162, 149-155 (2003).
31. Ma PC, Blaszkowsky L, Bharti A et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 23(1A), 49-62 (2003).
32. Sabbatini R, Federico M, Morselli M et al. Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy. J. Clin. Oncol. 18(9), 1914-1920 (2000).
33. Yamashita JI, Kurusu Y, Fujino N, Saisyoji T, Ogawa M. Detection of circulating tumor cells in patients with non-small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: a potential hazard for intraoperative hematogenous tumor cell dissemination. J. Thorac. Cardiovasc. Surg. 119(5), 899-905 (2000).
34. Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 25(33), 5194-5202 (2007).
35. Xenidis N, Perraki M, Kafousi M et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24(23), 3756-3762 (2006).
36. Stathopoulou A, Ntoulia M, Perraki M et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer 119(7), 1654-1659 (2006).
37. Racila E, Euhus D, Weiss AJ et al. Detection and characterization of carcinoma cells in the blood. Proc. Natl Acad. Sci. USA 95(8), 4589-4594 (1998).
38. Rosenberg R, Gertler R, Friederichs J et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 49(4), 150-158 (2002).
39. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
40. Tibbe AG, de Grooth BG, Greve J, Liberti PA, Dolan GJ, Terstappen LW. Cell analysis system based on immunomagnetic cell selection and alignment followed by immunofluorescent analysis using compact disk technologies. Cytometry 43(1), 31-37 (2001).
41. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 57(9), 1242-1255 (2011).
42. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc. Natl Acad. Sci. USA 86(8), 2617-2621 (1989).
43. Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J. Clin. Oncol. 17(7), 2015-2019 (1999).
44. Balic M, Dandachi N, Hofmann G et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B. Clin. Cytom. 68(1), 25-30 (2005).
45. Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(7), 2023-2029 (2007).
46. Cohen SJ, Alpaugh RK, Gross S et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(2), 125-132 (2006).
47. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
48. Cristofanilli M, Hayes DF, Budd GT et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23(7), 1420-1430 (2005).
49. Krebs MG, Hou JM, Sloane R et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J. Thorac. Oncol. 7(2), 306-315 (2012).
50. Hepp PGM, Rack BK, Tesch H et al. Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2 years after adjuvant chemotherapy in patients with primary breast cancer: the SUCCESS trial. J. Clin. Oncol. 29(Suppl.), Abstract 10626 (2011).
51. Rao CG, Chianese D, Doyle GV et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol. 27(1), 49-57 (2005).
52. Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J. Thorac. Oncol. 4(3), 281-283 (2009).
53. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A. 71(3), 154-162 (2007).
54. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008).
55. Wendel M, Bazhenova L, Boshuizen R et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys. Biol. 9(1), 016005 (2012).
56. Nieva J, Wendel M, Luttgen MS et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys. Biol. 9(1), 016004 (2012).
57. Marrinucci D, Bethel K, Kolatkar A et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys. Biol. 9(1), 016003 (2012).
58. Lazar DC, Cho EH, Luttgen MS et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys. Biol. 9(1), 016002 (2012).
59. Cho EH, Wendel M, Luttgen M et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys. Biol. 9(1), 016001 (2012).
60. Marrinucci D, Bethel K, Bruce RH et al. Case study of the morphologic variation of circulating tumor cells. Hum. Pathol. 38(3), 514-519 (2007).
61. Marrinucci D, Bethel K, Lazar D et al. Cytomorphology of circulating colorectal tumor cells: a small case series. J. Oncol. 2010, 861341 (2010).
62. Marrinucci D, Bethel K, Luttgen M, Bruce RH, Nieva J, Kuhn P. Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch. Pathol. Lab. Med. 133(9), 1468-1471 (2009).